WALDENSTRÖM MACROGLOBULINEMIA
Clinical trials for WALDENSTRÖM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTRÖM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTRÖM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new drug called BGB-16673 for people with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The goal is to find the best dose and see if it is safe and shrinks tumors. About 146 Chinese adults will take part in this …
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 17, 2026 08:50 UTC
-
New hope for rare blood cancer: pacritinib trial opens
Disease control Recruiting nowThis study tests a drug called pacritinib in 30 people with Waldenström macroglobulinemia whose cancer returned or did not respond to prior treatment. The goal is to see if the drug can shrink tumors and improve symptoms. Participants take the drug by mouth and are monitored for …
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Shayna Sarosiek, MD • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New Protein-Destroying drug shows promise for Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests an experimental drug, BGB-16673, designed to destroy a protein that helps certain blood cancers grow. It is for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to other treatments. The trial has two parts: first finding a…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 12, 2026 13:39 UTC